Quarterly report pursuant to Section 13 or 15(d)

Segment Information (Details)

v3.23.3
Segment Information (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Oct. 01, 2022
Sep. 30, 2023
Oct. 01, 2022
Segment Reporting Information [Line Items]        
Revenues $ 0 $ 0 $ 0 $ 0
Gross profit 0 0 0 0
Operating income (loss) (764) (611) (2,923) (1,950)
Depreciation and amortization     1,090 2
Interest (income) expense, net (758) (410) (1,598) (575)
Net income (loss) before income taxes (267) 217 (1,094) 2,609
Continuing Operations And Discontinuing Operations        
Segment Reporting Information [Line Items]        
Revenues 0 8,587 3,795 28,449
Gross profit 0 1,034 (197) 4,536
Operating income (loss) (764) (1,825) 11,235 6,066
Depreciation and amortization 363 77 1,186 347
Interest (income) expense, net (758) (130) (1,417) 123
Net income (loss) before income taxes (267) (1,965) 12,882 8,127
Segment Reconciling Items | Discontinued operations        
Segment Reporting Information [Line Items]        
Revenues 0 8,587 3,795 28,449
Gross profit 0 1,034 (197) 4,536
Operating income (loss) 0 (1,214) 14,158 8,016
Depreciation and amortization 0 77 96 347
Interest (income) expense, net 0 280 181 698
Net income (loss) before income taxes 0 (2,182) 13,976 5,518
Biotechnology | Operating Segments | Biotechnology        
Segment Reporting Information [Line Items]        
Revenues 0 0 0 0
Gross profit 0 0 0 0
Operating income (loss) (764) (611) (2,923) (1,950)
Depreciation and amortization 363 0 1,090 0
Interest (income) expense, net (758) (410) (1,598) (575)
Net income (loss) before income taxes $ (267) $ 217 $ (1,094) $ 2,609